BiotechTube

AK112

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gynecologic Cancer

Conditions

Gynecologic Cancer, Cancer Metastatic, Ovarian Neoplasms, Cervical Neoplasm, Endometrial Neoplasms

Trial Timeline

Apr 9, 2021 → May 10, 2024

NCT ID
NCT04870177

About AK112

AK112 is a phase 2 stage product being developed by Akeso for Gynecologic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04870177. Target conditions include Gynecologic Cancer, Cancer Metastatic, Ovarian Neoplasms.

What happened to similar drugs?

0 of 2 similar drugs in Gynecologic Cancer were approved

Approved (0) Terminated (0) Active (2)
🔄Ciprofol + PropofolHaisco Pharmaceutical GroupPhase 3
🔄FlosealBaxterPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (7)

NCT IDPhaseStatus
NCT07158840Phase 2Recruiting
NCT07010263Phase 3Recruiting
NCT05432492Phase 2Completed
NCT04900363Phase 1/2Completed
NCT04870177Phase 2Completed
NCT04597541Phase 1/2Completed
NCT04047290Phase 1Completed

Competing Products

13 competing products in Gynecologic Cancer

See all competitors
ProductCompanyStageHype Score
IMGN151 + Carboplatin + Bevacizumab + OlaparibAbbViePhase 2
42
Durvalumab + TremelimumabAstraZenecaPhase 1
21
PembrolizumabMerckPhase 1
29
Atezolizumab + RucaparibRochePhase 1
29
Vigil + AtezolizumabRochePhase 2
35
darbepoetin alfa + recombinant human erythropoietin (rHuEPO)AmgenPhase 2
35
Oral apixaban + Subcutaneous enoxaparinBristol Myers SquibbPhase 2
35
Ciprofol + PropofolHaisco Pharmaceutical GroupPhase 3
40
FlosealBaxterPhase 3
33
FloSeal applicationBaxterPre-clinical
23
IPH2201Innate PharmaPhase 1
19
Neoantigen specific TCR-T cell drug product + Aldesleukin (IL-2)Alaunos TherapeuticsPhase 1/2
14
Neoantigen specific TCR-T cell drug productAlaunos TherapeuticsPre-clinical
16